featured
Efficacy and Safety of Oral Tyrosine Kinase 2 Inhibitor PF-06826647 in Managing Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
J Am Acad Dermatol 2022 Apr 06;[EPub Ahead of Print], C Tehlirian, RSP Singh, V Pradhan, ES Roberts, S Tarabar, E Peeva, MS Vincent, JD GaleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.